Physician
University Family Physicians, INC.
University Family Physicians, INC. was paid $65.43M by Medicaid between Jan 2018 and Dec 2024, across 260 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 24% of everything it billed.
33Billing provider infoUNIVERSITY FAMILY PHYSICIANS, INC.
INDIANAPOLIS, IN 46202
INDIANAPOLIS, IN 46202
33aNPI1043275787assigned 04/18/2006
33bProvider typeHospice and Palliative Medicine (Family Medicine) Physician
28Total paid$65.43M
24GClaims1,198,803
24DCodes billed260
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 177,603 | $3.44M | |
| 2019 | 162,953 | $7.86M | |
| 2020 | 135,045 | $7.17M | |
| 2021 | 173,478 | $10.98M | |
| 2022 | 197,120 | $13.18M | |
| 2023 | 208,067 | $13.29M | |
| 2024incomplete | 144,537 | $9.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 171,971 | 143,704 | $15.98M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 22% | 211,370 | 176,419 | $14.62M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 8.6% | 106,584 | 94,042 | $5.63M |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 6.7% | 98,555 | 34,365 | $4.38M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 6.1% | 27,055 | 23,623 | $3.98M |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 4.9% | 44,380 | 17,241 | $3.22M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.3% | 17,452 | 14,928 | $1.49M |
| 88307 | 2.2% | 15,823 | 13,964 | $1.41M | |
| 99223 | Prolong inpt eval add15 m | 1.5% | 8,122 | 6,982 | $972K |
| 92015 | Determination of refractive state | 1.4% | 74,424 | 64,912 | $923K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.3% | 56,295 | 48,704 | $823K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | 1.1% | 6,792 | 5,371 | $748K |
248 more codes
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.0% | 8,033 | $677K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 8,431 | $653K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 7,550 | $634K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 4,666 | $572K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 6,118 | $549K |
| 92134 | <1% | 22,844 | $534K | |
| 36224 | <1% | 268 | $503K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 19,594 | $464K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 7,173 | $460K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 8,475 | $360K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 4,156 | $332K |
| 92201 | <1% | 14,945 | $316K | |
| 88342 | <1% | 8,007 | $237K | |
| 67228 | <1% | 674 | $223K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 162 | $217K |
| 20610 | <1% | 5,407 | $214K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 4,351 | $194K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 2,446 | $192K |
| 99205 | Prolong outpt/office vis | <1% | 1,131 | $191K |
| 36226 | <1% | 168 | $188K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 2,914 | $188K |
| 88173 | <1% | 3,097 | $182K | |
| 88189 | <1% | 2,565 | $170K | |
| 59425 | <1% | 2,104 | $170K | |
| 85060 | <1% | 9,197 | $168K | |
| 88112 | <1% | 7,584 | $157K | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 7,938 | $153K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 4,862 | $153K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 92 | $151K |
| 88350 | <1% | 1,054 | $141K | |
| 92060 | <1% | 2,154 | $141K | |
| 20611 | <1% | 2,069 | $140K | |
| 92226 | <1% | 6,148 | $135K | |
| 88304 | <1% | 11,368 | $128K | |
| 88341 | <1% | 1,855 | $107K | |
| 88108 | <1% | 5,074 | $82K | |
| 83020 | <1% | 3,800 | $66K | |
| 90686 | <1% | 19,558 | $66K | |
| 92250 | <1% | 1,816 | $57K | |
| 88313 | <1% | 2,282 | $56K | |
| 84165 | <1% | 4,175 | $50K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 808 | $48K |
| 67311 | <1% | 54 | $45K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 141 | $41K |
| 92083 | <1% | 2,147 | $40K | |
| G0452 | Molecular pathology procedure; physician interpretation and report | <1% | 698 | $35K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 780 | $33K |
| 76942 | <1% | 880 | $32K | |
| 88346 | <1% | 1,000 | $28K | |
| 88312 | <1% | 831 | $28K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 4,677 | $27K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 304 | $25K |
| 92136 | <1% | 992 | $24K | |
| 90474 | <1% | 1,405 | $20K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,834 | $20K |
| 99221 | <1% | 280 | $19K | |
| 95886 | <1% | 165 | $18K | |
| 92133 | <1% | 1,195 | $17K | |
| 88348 | <1% | 326 | $17K | |
| 96040 | <1% | 380 | $15K | |
| 86077 | <1% | 395 | $14K | |
| 92225 | <1% | 662 | $13K | |
| 90671 | <1% | 539 | $11K | |
| 88172 | <1% | 550 | $11K | |
| 87428 | <1% | 300 | $10K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,081 | $10K |
| 99442 | <1% | 838 | $9K | |
| 83655 | <1% | 941 | $9K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,200 | $8K |
| 81003 | <1% | 5,705 | $8K | |
| 88302 | <1% | 1,342 | $8K | |
| 64644 | <1% | 241 | $8K | |
| 64450 | <1% | 219 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,175 | $7K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,536 | $7K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 451 | $7K |
| 99460 | <1% | 69 | $7K | |
| 88311 | <1% | 923 | $7K | |
| 92025 | <1% | 324 | $7K | |
| 95874 | <1% | 615 | $6K | |
| 76882 | <1% | 191 | $6K | |
| 90656 | <1% | 1,088 | $5K | |
| 99381 | <1% | 70 | $5K | |
| 85027 | <1% | 4,791 | $5K | |
| 85097 | <1% | 99 | $5K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,489 | $5K |
| 86334 | <1% | 321 | $4K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 290 | $4K |
| V2020 | Frames, purchases | <1% | 195 | $4K |
| 0071A | <1% | 135 | $4K | |
| 88331 | <1% | 235 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 421 | $4K |
| 90670 | <1% | 3,466 | $4K | |
| 99383 | <1% | 55 | $4K | |
| 83735 | <1% | 3,565 | $4K | |
| V2755 | U-v lens, per lens | <1% | 213 | $4K |
| 99152 | <1% | 86 | $3K | |
| 95908 | <1% | 30 | $3K | |
| 99385 | <1% | 108 | $3K | |
| 99441 | <1% | 398 | $3K | |
| 76937 | <1% | 203 | $3K | |
| 92020 | <1% | 352 | $3K | |
| 99173 | <1% | 1,851 | $3K | |
| 59426 | <1% | 174 | $3K | |
| 64643 | <1% | 92 | $3K | |
| 0072A | <1% | 69 | $2K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 401 | $2K |
| 99218 | <1% | 17 | $2K | |
| 99417 | Prolong home eval add 15m | <1% | 54 | $2K |
| 80053 | Comprehensive metabolic panel | <1% | 859 | $2K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 87 | $2K |
| 92002 | <1% | 68 | $2K | |
| 96127 | <1% | 420 | $2K | |
| 90677 | <1% | 582 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 71 | $2K |
| 82948 | <1% | 2,063 | $2K | |
| 80076 | <1% | 984 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 124 | $2K |
| 0124A | <1% | 147 | $1K | |
| 86880 | <1% | 788 | $1K | |
| 86901 | <1% | 1,637 | $1K | |
| 86900 | <1% | 1,625 | $1K | |
| 64642 | <1% | 33 | $1K | |
| 88300 | <1% | 508 | $1K | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 354 | $1K |
| 81025 | <1% | 1,038 | $1K | |
| 90688 | <1% | 172 | $1K | |
| 82947 | <1% | 2,221 | $1K | |
| 82247 | <1% | 1,033 | $1K | |
| 90698 | <1% | 3,052 | $1K | |
| 85610 | <1% | 1,200 | $1K | |
| 99225 | <1% | 84 | $1K | |
| 85018 | <1% | 522 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 592 | $1K |
| 88188 | <1% | 18 | $1K | |
| 99283 | Emergency room visit (moderate) | <1% | 21 | $1K |
| 82565 | <1% | 1,886 | $986.00 | |
| 82310 | <1% | 1,758 | $961.00 | |
| 84132 | <1% | 1,857 | $956.16 | |
| 84295 | <1% | 1,818 | $923.40 | |
| 82374 | <1% | 1,628 | $915.02 | |
| 84166 | <1% | 69 | $910.15 | |
| 82435 | <1% | 1,631 | $904.10 | |
| 88360 | <1% | 145 | $887.22 | |
| 84520 | <1% | 1,711 | $883.81 | |
| 90717 | <1% | 18 | $868.42 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 91 | $810.99 |
| 84100 | <1% | 1,364 | $806.30 | |
| 99217 | <1% | 176 | $718.73 | |
| 86850 | <1% | 642 | $704.75 | |
| 0054A | <1% | 45 | $701.10 | |
| 80061 | Lipid panel | <1% | 86 | $698.94 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 74 | $642.50 |
| 90621 | <1% | 31 | $632.80 | |
| 90480 | <1% | 346 | $626.85 | |
| 96161 | <1% | 329 | $606.72 | |
| 99443 | <1% | 16 | $558.01 | |
| 76512 | <1% | 15 | $544.26 | |
| 82803 | <1% | 496 | $510.00 | |
| 99462 | <1% | 30 | $494.80 | |
| 99306 | Prolong nursin fac eval 15m | <1% | 12 | $485.08 |
| 83992 | <1% | 313 | $480.00 | |
| 0081A | <1% | 19 | $459.20 | |
| 80349 | <1% | 502 | $441.75 | |
| 90473 | <1% | 41 | $439.40 | |
| 99401 | <1% | 50 | $435.74 | |
| 81002 | <1% | 340 | $415.85 | |
| 90734 | <1% | 366 | $410.00 | |
| 80345 | <1% | 626 | $378.96 | |
| 80348 | <1% | 314 | $353.46 | |
| 80346 | <1% | 324 | $351.96 | |
| 80326 | <1% | 312 | $351.96 | |
| 80365 | <1% | 314 | $350.49 | |
| 80356 | <1% | 311 | $350.49 | |
| 80354 | <1% | 311 | $350.49 | |
| 80373 | <1% | 311 | $350.49 | |
| 80372 | <1% | 311 | $350.49 | |
| 80358 | <1% | 310 | $348.99 | |
| 0111A | <1% | 19 | $332.10 | |
| 88160 | <1% | 13 | $289.29 | |
| 90680 | <1% | 1,339 | $280.37 | |
| 84075 | <1% | 338 | $256.00 | |
| 84450 | <1% | 338 | $256.00 | |
| 84155 | <1% | 342 | $253.02 | |
| 84460 | <1% | 336 | $253.00 | |
| 82040 | <1% | 344 | $252.75 | |
| 90651 | <1% | 459 | $250.47 | |
| 80367 | <1% | 311 | $232.50 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 20 | $225.00 |
| 0003A | <1% | 16 | $223.26 | |
| 83690 | <1% | 288 | $223.08 | |
| 90715 | <1% | 332 | $210.62 | |
| 99201 | <1% | 14 | $183.29 | |
| 85730 | <1% | 124 | $174.30 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 37 | $146.80 |
| 85384 | <1% | 36 | $141.20 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 20 | $137.05 |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 296 | $136.16 |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 14 | $135.00 |
| 87040 | <1% | 74 | $121.09 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 174 | $111.00 |
| 99358 | Prolong nursin fac eval 15m | <1% | 120 | $103.05 |
| 90732 | <1% | 222 | $99.24 | |
| 83605 | <1% | 104 | $99.00 | |
| 84484 | <1% | 123 | $94.40 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 278 | $84.00 |
| 90744 | <1% | 663 | $79.06 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 77 | $68.14 |
| 81001 | <1% | 247 | $65.25 | |
| 99177 | <1% | 13 | $45.87 | |
| 82044 | <1% | 17 | $31.15 | |
| 90672 | <1% | 88 | $27.79 | |
| 90647 | <1% | 273 | $26.76 | |
| 82962 | <1% | 62 | $25.63 | |
| 85014 | <1% | 139 | $23.71 | |
| 80320 | <1% | 61 | $20.55 | |
| 90685 | <1% | 14 | $18.49 | |
| 82248 | <1% | 45 | $12.00 | |
| 87210 | <1% | 96 | $10.26 | |
| 87503 | <1% | 13 | $6.00 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 13 | $6.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16 | $0.41 |
| G0008 | Administration of influenza virus vaccine | 0% | 263 | $0.00 |
| 90723 | 0% | 108 | $0.00 | |
| 91307 | 0% | 337 | $0.00 | |
| 88309 | 0% | 157 | $0.00 | |
| 90619 | 0% | 12 | $0.00 | |
| 91317 | 0% | 25 | $0.00 | |
| 93000 | 0% | 56 | $0.00 | |
| 59430 | 0% | 83 | $0.00 | |
| 91305 | 0% | 85 | $0.00 | |
| 90697 | 0% | 12 | $0.00 | |
| 36416 | 0% | 13 | $0.00 | |
| 90696 | 0% | 14 | $0.00 | |
| 99386 | 0% | 13 | $0.00 | |
| 82150 | 0% | 12 | $0.00 | |
| 90649 | 0% | 52 | $0.00 | |
| 90633 | 0% | 792 | $0.00 | |
| 90681 | 0% | 57 | $0.00 | |
| 91308 | 0% | 44 | $0.00 | |
| 91300 | 0% | 41 | $0.00 | |
| 88321 | 0% | 246 | $0.00 | |
| 90687 | 0% | 13 | $0.00 | |
| 91312 | 0% | 66 | $0.00 | |
| 90710 | 0% | 41 | $0.00 | |
| 2022F | 0% | 26 | $0.00 | |
| 90648 | 0% | 12 | $0.00 | |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOLEMAN, JUDITH (CFO)
| Provider | Location | Paid |
|---|---|---|
| Indiana Clinic Critical Care LLC | Indianapolis, IN | $12.48M |
| University Surgeons, INC. | Indianapolis, IN | $2.52M |
| University Vascular Surgery, INC | Indianapolis, IN | $459K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.